Study backs Vasomedical's EECP (external counterpulsation) heart failure therapy
This article was originally published in Clinica
Evidence is growing to support Vasomedical's noninvasive external counterpulsation (EECP) therapy, after a study showed the technology was able to significantly improve cardiac output and quality of life in patients with congestive heart failure (CHF).
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.